Advertisement


Marlana M. Orloff, MD, on Metastatic Uveal Melanoma: First-Line Therapy for HLA-A2–Negative Disease

ASCO 2026

Advertisement

Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract LBA9503). 



Related Videos

Breast Cancer

Jame Abraham, MD, FACP, on First Results of the OPTIMA Trial in Breast Cancer: Expert Perspective

Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment in mostly node-positive patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500). 

Breast Cancer

Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03

Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).

Leukemia

Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?

Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL) overall, by age, and by treatment (Abstract 7042). 

Leukemia

Daniel A. Ermann, MD, on Two Agents in Treatment-Naive Patients With CLL: Real-World Treatment and Survival Outcomes

Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-line treatment for patients with chronic lymphocytic leukemia (CLL) based on overall survival and time to next treatment (Abstract 7045). 

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Advertisement

Advertisement




Advertisement